North America Blood Culture Tests Market

North America Blood Culture Tests Market (2023 to 2028)

The size of the North America Blood Culture Tests Market is expected to grow at 9.32% CAGR from 2023 to 2028. It is projected that the North American market was valued at USD 21.70 billion in 2022 and is anticipated to reach USD 33.94 billion by 2028.

Technological advancements in this area are majorly accelerating the North American blood culture tests market. It helps the blood culture tests provide superior quality, accuracy, and reliability in diagnosing the diseases and evading unnecessary healthcare costs, adding fuel to this region's growth. Growing R & D activities for novel products, increasing healthcare expenditure by public and private organizations, uplifts the development of the U.S. blood culture tests market. The increasing adoption rate of the latest technologies in patients, including multiplex real-time PCR system, molecular method and mass spectrometry, and electrospray ionization. Also, growth in government and private organizations makes proposals to bring out the awareness in people about the bacteria borne health conditions driving the market growth in the region.

The blood culture tests cost is increasing as 250,000 bloodstream infections are occurring every year, leading to the cause of suffering and deaths as the death rate goes up to 35% and costs massive per test in the U.S., which is expected to be hindering the market growth during the forecast period. The scarcity of experienced laboratory technicians is limiting the blood culture tests market over the period. Lack of reimbursement policies is impeding the market.

This research report on the North American Blood Culture Tests Market has been segmented & sub-segmented into the following categories:

By Product:

• Consumables
  • Blood Culture Media    
    • Aerobic Blood Culture Media
    • Pediatric Aerobic Blood Culture Media
    • Anaerobic Blood Culture Media
    • Mycobacterial Blood Culture Media
    • Fungi Blood Culture Media
  • Assay Kits & Reagents   
  • Blood Culture Accessories
• Instruments
  • Automated Blood Culture Systems      
  • Supporting Laboratory Equipment       
    • Incubators
    • Colony Counters
    • Microscopes
    • Gram Stainers
• Software and Services

By Technology:

• Culture-Based Technology
• Molecular Technologies
  • Microarrays
  • PCR (Polymerase Chain Reaction)       
  • PNA-FiSH (Peptide Nucleic Acid – Fluorescent in Situ Hybridization)       
• Proteomics Technology    

By Application:

• Bacteremia
• Fungemia
• Mycobacterial Detection

By End User:

• Hospital Laboratories
• Reference Laboratories

By Country:

• The United States
• Canada
• Rest of North America

Regional Analysis:

North America held the largest share in the market due to many large healthcare companies' local presence. Also, growing investments in R&D by manufacturers for new product development in this region is expected to propel the growth of the industry. In Canada, about 8,000 patients die annually because of hospital-acquired infections. According to WHO, about 250,000 cases of BSIs occur yearly in the U.S., and among them, around 80,000 patients in ICUs suffer from catheter-related BSIs. As a consequence, there is a high demand for advanced test products by hospitals and clinical diagnostics laboratories for the detection of bacterial, fungal, and mycobacterial infections

Some of the companies dominating the North American Blood Culture Tests market analyzed in this report are Cepheid, Inc., Nanosphere Inc., Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific Inc., IRIDICA, Beckman Coulter, Bruker Corporation, and T2 Biosystems.